1 hour ago
11
A federal judge has blocked the US government’s decision to place Chinese biotech firm WuXi AppTec on the Pentagon’s list of companies tied to China’s military, handing the company a significant legal win in a dispute that cuts to the heart of escalating US-China tensions in the life sciences sector.
The ruling comes after WuXi AppTec moved aggressively to challenge the Pentagon’s June 8 designation under Section 1260H, filing a lawsuit on June 11 in the US District Court for the District of Columbia and seeking a preliminary injunction on June 29. The company argued the classification lacked both legal and factual basis.
What the designation means, and why WuXi fought it
Section 1260H is the Pentagon’s mechanism for flagging companies it believes have ties to China’s military apparatus. Getting placed on this list doesn’t technically ban American companies from doing business with the named firm, but it does something arguably worse: it makes doing business with that firm radioactive.
For WuXi AppTec specifically, the designation threatened to trigger restrictions under the Biosecure Act provisions embedded in the FY2026 National Defense Authorization Act. Those provisions could cut the company off from US federal procurement and funding opportunities, a potentially devastating blow for a firm that derives roughly 70% of its revenue from the US market.
The Pentagon’s rationale centered on indirect ownership connections to China’s State-owned Assets Supervision and Administration Commission, known as SASAC, and alleged affiliations with the People’s Liberation Army. WuXi AppTec has firmly denied any military connections, stating it does not provide services to the PLA in any capacity.
Hong Kong-listed shares of WuXi AppTec dropped approximately 5% following news of the initial designation, reflecting the market’s immediate concern about the company’s access to its most important revenue source.
The legal battle and its broader stakes
WuXi AppTec operates as one of the world’s largest contract development and manufacturing organizations, or CDMOs, and runs major facilities in the US. The company has said it intends to pursue every available legal avenue to contest the designation.
Congressional efforts to target WuXi entities date back to at least 2024, when lawmakers began raising concerns about Chinese biotech firms’ access to sensitive American health data and their potential roles in China’s military-civil fusion strategy. The Biosecure Act itself was partly crafted with WuXi in mind, reflecting a broader legislative push to decouple critical biotech supply chains from Chinese firms.
The judge’s intervention doesn’t mean WuXi has won. It means the court found enough merit in the company’s arguments to pause the designation’s effects while the full case plays out.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
English (US) ·